Prognostic Impact of Mesenteric Lymph Node Status on Digestive Resection Specimens During Cytoreductive Surgery for Ovarian Peritoneal Metastases

Abstract

Background The most common mode of ovarian cancer (OC) spread is intraperitoneal dissemination, with the peritoneum as the primary site of metastasis. Cytoreductive surgery (CRS) with chemotherapy is the primary treatment. When necessary, a digestive resection can be performed, but the role of mesenteric lymph nodes (MLNs) in advanced OC remains unclear, and its significance in treatment and follow-up evaluation remains to be determined. This study aimed to evaluate the prevalence of MLN involvement in patients who underwent digestive resection for OC peritoneal metastases (PM) and to investigate its potential prognostic value. Methods This retrospective, descriptive study included patients who underwent CRS with curative intent for OC with PM between 1 January 2007 and 31 December 2020. The study assessed MLN status and other clinicopathologic features to determine their prognostic value in relation to overall survival (OS) and progression-free survival (PFS). Results The study enrolled 159 women with advanced OC, 77 (48.4%) of whom had a digestive resection. For 61.1% of the patients who underwent digestive resection, MLNs were examined and found to be positive in 56.8%. No statistically significant associations were found between MLN status and OS (p = 0.497) or PFS ((p = 0.659). Conclusions In anatomopathologic studies, MLNs are not systematically investigated but are frequently involved. In the current study, no statistically significant associations were found between MLN status and OS or PFS. Further prospective studies with a systematic and standardized approach should be performed to confirm these findings.

CRISPR/Cas9-based genome-wide screening for metastasis ability identifies FCGR1A regulating the metastatic process of ovarian cancer by targeting LSP1

“…Abdominal metastasis is a major cause of poor prognosis in OC patients (Channawi et al 2023a ). Our study is the first to identify FCGR1A as a promoter of metastasis in ovarian cancer through the regulation of LSP1 genes.…”

“…This suggests that FCGR1A promotes tumor invasion by regulating LSP1, making it possible for FCGR1A to promote metastasis by modulating the function of immune cells in the peritoneal microenvironment. In previous studies, LSP1 was reported to be involved in immune escape, and LSP1 secreted by abnormally activated tumor cells regulates metastasis-associated macrophages (Channawi et al 2023b ). The lymphocyte-specific protein LSP1 regulates macrophage phagocytosis and the migration of immune cells.…”